ID
ISEE

Integral Derivatives’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Integral Derivatives’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,531
Closed -$56K – 1426
2016
Q4 		$56K Buy
+11,531
New +$342K ﹤0.01% 1087

Other funds holding ISEE

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Integral Derivatives's ISEE Position: Q1 2017 in Review

Integral Derivatives sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2017, closing a stake of 11,531 shares — an estimated $56K sold.

Integral Derivatives first reported a position in ISEE in Q4 2016 and held it in 1 quarter. The position peaked at $56K in Q4 2016. 100 funds tracked by Wall St. Rank hold ISEE as of Q1 2017.

  • Integral Derivatives reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Integral Derivatives sold 11,531 IVERIC bio, Inc. Common Stock shares in Q1 2017, an estimated $56K.
  • Integral Derivatives first reported a position in IVERIC bio, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • Integral Derivatives's IVERIC bio, Inc. Common Stock position peaked at $56K in Q4 2016.
  • 100 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.